Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Gubra AS's Debt-to-EBITDA or its related term are showing as below:
FRA:PI3'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.81 Med: 0.29 Max: 4.73
Current: 0.05
During the past 7 years, the highest Debt-to-EBITDA Ratio of Gubra AS was 4.73. The lowest was -4.81. And the median was 0.29.
FRA:PI3's Debt-to-EBITDA is ranked better than 89.35% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs FRA:PI3: 0.05
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Gubra AS Debt-to-EBITDA Related Terms
Gubra AS Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Gubra AS's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PI3 vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Gubra AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gubra AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Gubra AS (FRA:PI3) has a Debt-to-EBITDA of -0.29 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Gubra AS. According to the industry distribution chart, Gubra AS ranks #31 out of 291 companies in the Biotechnology industry, placing it in the top 10.7%.
Is Gubra AS's Debt-to-EBITDA too high?
Gubra AS's current Debt-to-EBITDA is -0.29. Based on the distribution chart, Gubra AS ranks #31 out of 291 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gubra AS has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #31 out of 291 companies for Debt-to-EBITDA. This places Gubra AS in the top 11% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Gubra AS. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gubra AS's current Debt-to-EBITDA is -0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (FRA:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €386.57, compared to a current price of €44.76 — trading 88.4% below its estimated fair value. The current Debt-to-EBITDA is -0.29. Gubra AS's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Gubra AS (FRA:PI3), the current Debt-to-EBITDA is -0.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (FRA:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €44.76 is trading 88.4% below its estimated GF Value™ of €386.57.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for FRA:PI3:
Debt-to-EBITDA: -0.29
GF Value™: €386.57 vs. price of €44.76 (88.4% below fair value)
No single metric tells the full story. See the FRA:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
78GF Score
Get the complete analysis for FRA:PI3
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PI3 has been successfully added to your 
